ReviewNature biotechnology2012
Combinatorial drug therapy for cancer in the post-genomic era.
Review in Nature biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 487 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
487 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Molecular Systems Architecture of Fibrotic Lung Microenvironment in Idiopathic Pulmonary Fibrosis.Cells · 2026Pooled it
- Survival prediction landscape: an in-depth systematic literature review on activities, methods, tools, diseases, and databases.Frontiers in artificial intelligence · 2024Pooled it
- Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.Journal for immunotherapy of cancer · 2021Pooled it
- Time-Resolved Network Entropy Analysis Identifies a CTNND1-VAV3 Subnetwork in Gefitinib-Resistant NSCLC.International journal of molecular sciences · 2026Article
- Metabolic Activation-Dependent Anti-Liver Cancer Activity and Organ-Specific Toxicity of Retrorsine From Fanhuncao (Jacobaea cannabifolia and J. litvinovii).Archiv der Pharmazie · 2026Article
- Mitochondria-Targeted Cancer Therapy Using an Endogenous Stimuli-Responsive Prodrug With Aggregation-Induced-Emission Features.Chemistry, an Asian journal · 2026Article
- Developing a Phosphodiesterase 10A Inhibitor as a Novel Therapeutic Agent for Triple-Negative Breast Cancer.Cells · 2026Article
- Bacteria-mimicking cancer cells reprogram macrophages via multiple pattern recognition receptor pathways for cancer immunotherapy.Signal transduction and targeted therapy · 2026Article
- Expression of ABCB1, ABCB5, and ABCG2 Transporters in Human Renal Cell Carcinoma and Their Underlying Signaling Pathways.Current issues in molecular biology · 2026Article
- Molecular Insights into the Interaction Between Metformin and Caffeine: The Time-Dependent Antagonism and Modulation of p53 Signaling in Cancer Cells.Molecules (Basel, Switzerland) · 2026Article
- Engineered membrane-coated nanoparticles enhance ferroptosis and microtubule inhibition in prostate cancer.Journal of materials science. Materials in medicine · 2026Article
- Integrating multi-omics data for next-generation cancer research and precision medicine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- A causal inference framework for identifying essential genes to enhance drug synergy prediction.Bioinformatics (Oxford, England) · 2026Article
- Mechanism-based prediction of drug synergy via network controllability analysis of therapeutic pathways in intractable diseases.iScience · 2026Article
- Altered chromatin accessibility and nucleosome positioning landscape upon HDAC and LSD1 inhibition in cancer cell.bioRxiv : the preprint server for biology · 2026Article
- One-hot news: drug synergy models shortcut molecular features.Bioinformatics (Oxford, England) · 2026Article
- Life as Counterfactual Geometry: An Adversarial Theory of Biological Function.Entropy (Basel, Switzerland) · 2026Article
- The application of experimental models for the drug discovery for digestive tumors.Molecular cancer · 2026Review
- Buddlejasaponin IV inhibits proliferation and migration via STAT3 suppression in gefitinib-resistant non-small cell lung cancer cells.BMC complementary medicine and therapies · 2026Article
- scLong: a billion-parameter foundation model for capturing long-range gene context in single-cell transcriptomics.Nature communications · 2026Article
427 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted. Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups. This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach. However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility. One solution to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.
Indexed as
Identifiers
22781697What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.